Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.

Orforglipron, an Oral GLP-1 Receptor Agonist, in Early Type 2 Diabetes

Julio Rosenstock, David Cox, Max Denning · 2025 · New England Journal of Medicine

Abstract

To the Editor: The results of the ACHIEVE-1 trial, reported by Rosenstock et al. (Sept. 18 issue), 1 highlight the potential benefits of orforglipron. This small-molecule drug offers the convenience of oral administration without injections, which may enhance patient adherence. Its use without dietary restrictions also improves practicality. Pharmacologically, it acts as a partial agonist that promotes cyclic AMP signaling more strongly than β-arrestin recruitment at the glucagon-like peptide-1 (GLP-1) receptor, which potentially reduces receptor desensitization, although its clinical relevance requires further study. Current clinical data are mainly from the ACHIEVE trials, and long-term safety, as well as cardiovascular risk reduction . . .

Overview

Integrity signals

Registry

Crossref · 10.1056/nejmc2515117

Cites

12 of 12 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 12 references

Cited by

See all 3

Metadata

Authors
Rosenstock, J., Cox, D., & Denning, M.
Affiliations
  • Medical City Dallas Hospital (US)
  • Eli Lilly (United States) (US)
Venue
New England Journal of Medicine
Published
2025-12-04
Volume
393
Issue
22
Pages
2276-2279
ISSN
  • 0028-4793 (ISSN-L)
  • 1533-4406
OpenAlex
W4417035355
Cited by
2
References
12
Citations by year
2026: 2
Type
journal article
Language
en
Open access
closed
Locations
  • New England Journal of Medicine (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
  • Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
Keywords
orforglipron, GLP-1 receptor agonists, type 2 diabetes, early type 2 diabetes, oral administration, cAMP signaling, beta-arrestin, receptor desensitization, long-term safety, cardiovascular risk

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Orforglipron, an Oral GLP-1 Receptor Agonist, in Early Type 2 Diabetes. https://app.cochat.ai/papers/10.1056/nejmc2515117
The paper
Rosenstock, J., Cox, D., & Denning, M. (2025). Orforglipron, an Oral GLP-1 Receptor Agonist, in Early Type 2 Diabetes. New England Journal of Medicine. https://doi.org/10.1056/nejmc2515117

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.